Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy

By sjmartinez • January 16, 2025

Jaiswal V, Hanif M, Mashkoor Y, Jaiswal A, Prasad T, Rajak K, Khan MS, Mentz RJ, Fonarow GC. Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy. JACC Adv. 2024 Nov 15;3(12):101405. doi: 10.1016/j.jacadv.2024.101405. PMID: 39817087; PMCID: PMC11734025.

Tags: amyloidosis, Cardiology/Epi, Outcomes, Publications, SGLT2 inhibitors, transthyretin amyloid cardiomyopathy

Systemic Inflammation and Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease

Sandhu AT, Furst A, Rodriguez F, Kalwani N, Maron D, Nallamshetty S, Din N, Zitko K, Khachatourian K, Skaar JR, Tonnu-Mihara I. Systemic Inflammation and[...]

Breaking Barriers to Transplantation: Desensitization with Daratumumab in Peripartum Cardiomyopathy

Okwuosa I, Kumar A, Choi SM, Kamath M, Vellanki S. Breaking Barriers to Transplantation: Desensitization with Daratumumab in Peripartum Cardiomyopathy. Can J Cardiol. 2026 Apr[...]

Systems Genetics Reveals ITIH5 as a Key Mediator of Adipocyte-Endothelial Crosstalk

Zhou M, Velez LM, Kwan D, Moses L, Johnson CD, Nguyen CM, Mott L, Gamie F, Fouladi M, Bae H, Verlande A, Arneson D, Petrus[...]